

Clinical Policy: Casgevy – Pharmacy Prior Approval Criteria

Reference Number: WNC.CP.300

Coding Implications

Last Review Date:

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Note: When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Description¹ - This policy discusses medical necessity criteria for Casgevy (exagamglogene autotemcel) Pharmacy Prior Approval Criteria.

Therapeutic Class Code: N1K

Therapeutic Class Description: Gene Therapy Agents- CD34+ Hematopoietic Stem Cells

Policy/Criteria¹

- I.** WellCare of North Carolina[®] shall cover Casgevy when **ALL** the following requirements are met:
- A.** Member shall be enrolled on the date of service and may have service restrictions due to their eligibility category that would make them ineligible for this service;
 - B.** Member is ≥ 12 years of age; **AND**
 - C.** Provider has considered use of prophylaxis therapy for seizures prior to initiating myeloablative conditioning; **AND**
 - D.** Member has been screened and found negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus 1&2 (HIV-1/HIV-2) in accordance with clinical guidelines prior to collection of cells (leukapheresis); **AND**
 - E.** Must not be administered concurrently with live vaccines while immunosuppressed; **AND**
 - F.** Member does not have history of hypersensitivity to dimethyl sulfoxide (DMSO) or dextran 40; **AND**
 - G.** Member has not received other gene therapies [e.g. Lyfgenia[®] (lovotibeglogene autotemcel), Zynteglo[®] (betibeglogene autotemcel), etc.]**; **AND**
 - H.** Member will not receive therapy concomitantly with any of the following:
 - 1. Iron chelators for 7 days prior to mobilization and 6 months post-treatment (3 months post-treatment for non-myelosuppressive iron chelators); **AND**
 - 2. Disease-modifying agents (e.g. hydroxyurea, or crizanlizumab) for at least 8 weeks prior to mobilization and conditioning; **AND**
 - I.** Member is a candidate for autologous hematopoietic stem cell transplant (HSCT) and has not had prior HSCT; **AND**
 - J.** For Members under 18 years of age, the Member does not have a known and suitable 10/10 human leukocyte antigen matched related donor willing to participate in an allogenic HSCT; **AND**

CLINICAL POLICY WNC.CP.300
CASGEVY - PHARMACY PRIOR APPROVAL CRITERIA



- II. WellCare of North Carolina® shall cover Casgevy for SICKLE CELL DISEASE when ALL the following requirements are met:**
- A.** Member has a confirmed diagnosis of sickle-cell disease with one of the following genotypes: $\beta\text{S}/\beta\text{S}$ or $\beta\text{S}/\beta\text{0}$ or $\beta\text{S}/\beta+$ (Note: additional genotypes will be considered on a case-by-case basis based on disease severity) as determined by 1 of the following:
 - 1. Identification of significant quantities of sickle cell hemoglobin (HbS) with or without an additional abnormal β -globin chain variant by hemoglobin assay; **OR**
 - 2. Identification of biallelic *HBB* pathogenic variants where at least one allele is the p.Glu6Val pathogenic variant on molecular genetic testing; **AND**
 - B.** Member has symptomatic disease despite treatment with hydroxyurea at any point in the past OR add-on therapy (e.g. crizanlizumab etc.) OR has experienced intolerance; **AND**
 - C.** Member has experienced ≥ 2 serious Vaso-occlusive events/crises requiring hospitalization (VOE/VOC)* in the previous year while adhering to the above therapy; **AND**
 - D.** Member will be transfused prior to apheresis to a total Hb < 11 g/dL and a HbS level $< 30\%$ and patient will be transfused at least 8 weeks prior to initiation of myeloablative conditioning (with aforementioned Hb and HbS goals; **AND**
 - E.** Member will not receive granulocyte-colony stimulating factor (G-CSF) for the mobilization of hematopoietic stem cells (HSC) **AND**
 - F.** Must be prescribed in consultation with a board-certified hematologist with Sickle Cell Disease expertise.
- III. WellCare of North Carolina® shall cover Casgevy for Beta Thalassemia when ALL the following requirements are met:**
- A.** Member has a documented diagnosis of homozygous beta thalassemia or compound heterozygous beta thalassemia including β -thalassemia/hemoglobin E (HbE) as outlined by the following:
 - 1. Member diagnosis is confirmed by *HBB* sequence gene analysis showing biallelic pathogenic variants; **OR**
 - 2. Member has severe microcytic hypochromic anemia, absence of iron deficiency, anisopoikilocytosis with nucleated red blood cells on peripheral blood smear, and hemoglobin analysis that reveals decreased amounts or complete absence of hemoglobin A (HbA) and increased HbA₂ with or without increased amounts of hemoglobin F (HbF); **AND**
 - B.** Member has transfusion-dependent disease defined as a history of transfusions of at least 100 mL/kg/year or ≥ 10 units/year of packed red blood cells (pRBCs) in the 2 years preceding therapy; **AND**
 - C.** Member will be transfused prior to apheresis to a total Hb ≥ 11 g/dL for 60 days prior to myeloablative conditioning; **AND**
 - D.** Member does not have any of the following:
 - 1. Severely elevated iron in the heart (i.e., patients with cardiac T2* less than 10 msec by magnetic resonance imaging [MRI] or left ventricular ejection fraction [LVEF] $< 45\%$ by echocardiogram); **OR**
 - 2. Advanced liver disease [i.e., AST or ALT > 3 times the upper limit of normal (ULN), or direct bilirubin value > 2.5 times the ULN, or if a liver biopsy demonstrated bridging fibrosis or cirrhosis]

CLINICAL POLICY WNC.CP.300
CASGEVY - PHARMACY PRIOR APPROVAL CRITERIA

**VOE/VOC is defined as an event requiring a visit to a medical facility for evaluation which results in a diagnosis of such being documented due to one (or more) of the following: acute pain, acute chest syndrome, acute splenic sequestration, acute hepatic sequestration, priapism lasting > 2 hours AND necessitating subsequent interventions such as opioid pain management, non-steroidal anti-inflammatory drugs, RBC transfusion, etc.*

II. WellCare of North Carolina® shall **NOT RENEW** coverage.

III. WellCare of North Carolina’s® Duration of Approval is **ONE TREATMENT** course.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2024, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| CPT®* Codes | Description |
|-------------|-------------------------------------|
| J3392 | Casgevvy - exagamglogene autotemcel |

| Reviews, Revisions, and Approval | Reviewed Date | Approval Date |
|----------------------------------|---------------|---------------|
| Original Approval Date | | |

References

1. State of North Carolina Medicaid Outpatient Pharmacy Prior Approval Criteria - Casgevvy. [Program Specific Clinical Coverage Policies | NC Medicaid \(ncdhs.gov\)](https://www.ncdhs.gov/Program-Specific-Clinical-Coverage-Policies). Published January 1, 2025. Accessed January 3, 2025.

North Carolina Guidance

Eligibility Requirements

1. An eligible beneficiary shall be enrolled in the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise);
2. Provider(s) shall verify each Medicaid beneficiary’s eligibility each time a service is rendered.

CLINICAL POLICY WNC.CP.300
CASGEVY - PHARMACY PRIOR APPROVAL CRITERIA



3. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.

EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age

- 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]
Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary's physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary's right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

- I. that is unsafe, ineffective, or experimental or investigational.
- II. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider's documentation shows that the requested service is medically necessary "to correct or ameliorate a defect, physical or mental illness, or a condition" [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary's health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

EPSDT and Prior Approval Requirements

- If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
- **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below:

CLINICAL POLICY WNC.CP.300
CASGEVY - PHARMACY PRIOR APPROVAL CRITERIA



NCTracks Provider Claims and Billing Assistance Guide:

<https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html>

EPSDT provider page: <https://medicaid.ncdhhs.gov/>

Provider(s) Eligible to Bill for the Procedure, Product, or Service

To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

- i. meet Medicaid qualifications for participation;
- ii. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and
- iii. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

Compliance

Provider(s) shall comply with the following in effect at the time the service is rendered:

- A. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and
- B. All NC Medicaid's clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

Claims-Related Information

Provider(s) shall comply with the NC Tracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid's clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid:

- Claim Type - as applicable to the service provided:
Professional (CMS-1500/837P transaction)
Institutional (UB-04/837I transaction)
Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.
- International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) - Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.
- Code(s) - Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy. If no such specific CPT or HCPCS code exists, then the provider(s) shall report

CLINICAL POLICY WNC.CP.300

CASGEVY - PHARMACY PRIOR APPROVAL CRITERIA

the procedure, product or service using the appropriate unlisted procedure or service code.

Unlisted Procedure or Service

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions For Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service

- Modifiers - Providers shall follow applicable modifier guidelines.
- Billing Units - Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).
- Co-payments -
For Medicaid refer to Medicaid State Plan:
<https://medicaid.ncdhhs.gov/get-involved/nc-health-choice-state-plan>
- Reimbursement - Provider(s) shall bill their usual and customary charges. For a schedule of rates, refer to: <https://medicaid.ncdhhs.gov/>.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or

CLINICAL POLICY WNC.CP.300
CASGEVY - PHARMACY PRIOR APPROVAL CRITERIA

regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.